KaydedilenlerDerginizi ekleyin

Dergiler / Türk Onkoloji Dergisi / 2020 / Cilt: 35 - Sayı: 4

The Role of Pathology in Predicting ImmunotherapyResponse in Urogenital Tumors

Yasemin ÖZLÜK
Sayfa
492–496
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

PD-L1 expression by immunohistochemistry, tumor mutation burden and microsatellite instability status are mainly discussed.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Immune checkpoint inhibitors (ICI) are recently introduced in the management of various cancers.
📊
Temel Bulgular & Veri:There are three main immunotargets as follows: Cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1).
💡
Sonuç & Katkı:PD-L1 expression by immunohistochemistry, tumor mutation burden and microsatellite instability status are mainly discussed.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Immune checkpoint inhibitors (ICI) are recently introduced in the management of various cancers. There are three main immunotargets as follows: Cytotoxic T-lymphocyte antigen-4 (CTLA4), programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1). These three targets are under investigation for therapeutic, predictive and prognostic purposes in genitourinary cancers. There is a need for predictive biomarkers of immunotherapy to optimize treatment, to limit side-effects and to reduce the costs of therapy. This review focuses on the role of pathologic applications in the selection of patients with genitourinary cancer who are potentially responsive to immunotherapy. PD-L1 expression by immunohistochemistry, tumor mutation burden and microsatellite instability status are mainly discussed.

🔖

Bu Makaleye Atıf Yap

ÖZLÜK, Y. (2022). The Role of Pathology in Predicting ImmunotherapyResponse in Urogenital Tumors. Türk Onkoloji Dergisi, Cilt: 35 - Sayı: 4, 492–496. https://ajindex.com/articles/639134

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, et al. An Overview of Emerging Immunotargets of Genitourinary Tumors. Curr Drug Targets 2016;17(7):750–6
  2. Mehta K, Patel K, Parikh RA. Immunotherapy in genitourinary malignancies. J Hematol Oncol 2017;10(1):95
  3. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol 2017;8:561
  4. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012;1(8):1223–5
  5. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018–28
  6. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375(19):1856–67
  7. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015;373(19):1803–13
  8. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 2016;17(11):1590–8
  9. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375(19):1823–33. 10.Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387(10027):1540–50. 11.Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376(11):1015–26. 12.Hansen AR, Siu LL. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. JAMA Oncol 2016;2(1):15–6. 13.Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol 2016;34(26):3119–25. 14.Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D